MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)
Launched by AHS CANCER CONTROL ALBERTA · Apr 21, 2020
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Northern LIGHTs - 1 study, is exploring a new way to use MRI technology to improve cancer treatment. Traditionally, doctors use CT scans to locate tumors before delivering radiation therapy, but these scans sometimes don’t provide a clear picture. This study is testing a new machine called the Linac-MR, which combines MRI with radiation treatment to see if it can provide better images of tumors. The goal is to gather high-quality MRI images safely to help doctors visualize tumors more effectively for future patients.
To participate in this study, you need to be an adult aged 18 or older and be in good health to undergo high-dose radiation therapy as determined by your doctor. However, if you have certain conditions that prevent you from having an MRI, or if you cannot lie still during the scan, you may not be eligible. If you choose to take part, you can expect to help researchers learn more about this new technology, which could lead to better cancer treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults ≥ 18 years of age
- • Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist
- Exclusion Criteria:
- • Patients with contraindications for MRI
- • Patients who are unable to lie flat and still for the duration of the expected scan acquisition
- • Patients who are unable to provide informed consent
About Ahs Cancer Control Alberta
AHS Cancer Control Alberta is a leading clinical trial sponsor dedicated to advancing cancer treatment and research in Alberta, Canada. As part of Alberta Health Services, the organization focuses on optimizing patient care through innovative clinical trials that explore new therapeutic approaches and enhance existing treatment protocols. With a commitment to evidence-based practices, AHS Cancer Control Alberta collaborates with healthcare professionals and researchers to facilitate groundbreaking studies aimed at improving outcomes for cancer patients. Their mission encompasses not only the pursuit of scientific knowledge but also the integration of patient-centered care throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Nawaid Usmani, MD
Principal Investigator
Cross Cancer Institute, Alberta Health Services
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials